Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II safety and immunogenicity study of quadrivalent human papillomavirus (Types 6, 11, 16, 18) L1 virus-like particle (VLP) vaccine [human papillomavirus vaccine recombinant quadrivalent] in HIV infected children 7 to 12 years of age.

Trial Profile

Phase II safety and immunogenicity study of quadrivalent human papillomavirus (Types 6, 11, 16, 18) L1 virus-like particle (VLP) vaccine [human papillomavirus vaccine recombinant quadrivalent] in HIV infected children 7 to 12 years of age.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jun 2015

At a glance

  • Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
  • Indications Cervical cancer; Human papillomavirus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 29 Mar 2012 Additional lead trial centre and investigator identified as reported by ClinicalTrials.gov.
    • 08 Mar 2012 Results presented at the 19th Conference on Retroviruses and Opportunistic Infections.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top